Results 11 to 20 of about 54,164 (265)

Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection.

Cell Host and Microbe, 2023
Fecal microbiota transplantation (FMT) is highly effective in preventing recurrent Clostridioides difficile infection (rCDI). However, the mechanisms underpinning its clinical efficacy are incompletely understood.
Abbas Yadegar, Sepideh Pakpoor, F. Ibrahim, Ali Nabavi-Rad, Laura Cook, J. Walter, Anna M. Seekatz, K. Wong, T. Monaghan, D. Kao   +9 more
semanticscholar   +3 more sources

Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota

Nature Medicine, 2020
The involvement of host immunity in the gut microbiota-mediated colonization resistance to Clostridioides difficile infection (CDI) is incompletely understood.
Hiroko Nagao-Kitamoto, Jhansi L. Leslie, Sho Kitamoto, C. Jin, K. Thomsson, Merritt G. Gillilland, Peter Kuffa, Y. Goto, R. Jenq, Chiharu Ishii, A. Hirayama, Anna M. Seekatz, E. Martens, K. Eaton, J. Kao, S. Fukuda, P. Higgins, N. Karlsson, V. Young, N. Kamada   +19 more
semanticscholar   +3 more sources

Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis

EClinicalMedicine, 2020
Background Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection (CDI), but inconsistent effect rates and uncertain evidence levels have warranted caution.
S. M. Baunwall, M. Lee, M. Eriksen, B. Mullish, J. Marchesi, J. Dahlerup, C. Hvas   +6 more
semanticscholar   +3 more sources

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.

Clinical Infectious Diseases, 2021
This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI.
Stuart Johnson, V. Lavergne, Andrew M. Skinner, A. Gonzales-Luna, K. Garey, C. Kelly, M. Wilcox   +6 more
semanticscholar   +2 more sources

Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?

International Journal of Infectious Diseases, 2022
Recently, the recommendations for the treatment of Clostridioides difficile infection (CDI) have been updated. However, in addition to the clinical efficacy data, the drug of choice should ideally represent optimal antimicrobial stewardship, with an ...
Marcela Krutova, Mark Wilcox, Ed Kuijper
doaj   +1 more source

Variants at the MHC Region Associate With Susceptibility to Clostridioides difficile Infection: A Genome-Wide Association Study Using Comprehensive Electronic Health Records

Frontiers in Immunology, 2021
BackgroundClostridioides difficile is a major cause of healthcare-associated and community-acquired diarrhea. Host genetic susceptibility to Clostridioides difficile infection has not been studied on a large-scale.MethodsA total of 1,160 Clostridioides ...
Jiang Li, Yanfei Zhang, Alexandria L. Jilg, Donna M. Wolk, Harshit S. Khara, Amy Kolinovsky, David D. K. Rolston, Raquel Hontecillas, Josep Bassaganya-Riera, Marc S. Williams, Vida Abedi, Ming Ta Michael Lee   +11 more
doaj   +1 more source

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.

New England Journal of Medicine, 2022
BACKGROUND Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria.
P. Feuerstadt, T. Louie, B. Lashner, E. Wang, Liyang Diao, J. Bryant, M. Sims, Colleen S Kraft, Stuart H. Cohen, C. Berenson, L. Korman, Christopher B. Ford, Kevin D. Litcofsky, M. Lombardo, J. Wortman, Henry Wu, J. Auniņš, Christopher McChalicher, J. Winkler, B. McGovern, M. Trucksis, M. Henn, L. V. von Moltke   +22 more
semanticscholar   +1 more source

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Drugs, 2022
Recurrent Clostridioides difficile infection, associated with dysbiosis of gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic product consisting of a broad consortium of microbes prepared from human stool that is ...
S. Khanna, M. Assi, Christine Lee, David L. Yoho, T. Louie, W. Knapple, H. Aguilar, J. Garcia-Diaz, Gary P. Wang, S. Berry, Joe Marion, Xin Su, Tricia L. Braun, Lindy L. Bancke, P. Feuerstadt   +14 more
semanticscholar   +1 more source

Epidemiology of Clostridioides difficile Infection in Portugal: A Retrospective, Observational Study of Hospitalized Patients

Acta Médica Portuguesa, 2022
Introduction: Clostridioides difficile is the main cause of healthcare-associated diarrhea in Europe and North America. The aim of this study was to characterize the epidemiology and clinical burden of Clostridioides difficile infection among ...
Cláudia Nazareth, Inês Leitão, Ernestina Reis, Hugo Inácio, Filomena Martins, Elmano Ramalheira, Flávia Cunha, Carla Santos, Sara Lino, Hugo Moreira, Nadiya Kruptsala, Andrea Santos, Laura Paixão, Leonor Pássaro, Mónica Oleastro   +14 more
doaj   +1 more source

European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.

Clinical Microbiology and Infection, 2021
SCOPE In 2009, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first treatment guidance document for Clostridioides difficile infection (CDI). This document was updated in 2014.
J. van Prehn, E. Reigadas, E. Vogelzang, E. Bouza, A. Hristea, B. Guery, M. Krutova, T. Norén, F. Allerberger, J. Coia, A. Goorhuis, T. V. van Rossen, R. Ooijevaar, K. Burns, B. R. Scharvik Olesen, S. Tschudin-Sutter, M. Wilcox, M. Vehreschild, F. Fitzpatrick, E. Kuijper   +19 more
semanticscholar   +1 more source